Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell- mediated immune responses after treatment with an HIV-1 immunogen

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 641-648

  Moss, Ronald B ^a   Wallace, Mark R ^b   Giermakowska, Wieslawa K ^a   Webb, Erin ^a   Savary, Jay ^a   Chamberlin Brandt, Carolyn ^b   Theofan, Georgia ^a   Musil, Roy ^a   Richieri, Steven P ^a   Jensen, Fred C ^a   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; REGRESSION ANALYSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, INACTIVATED;

EID: 0032875488     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314924     Document Type: Article

References (31)

1. 1. Wahren B, Morfeldt-Mǎnsson L, Biberfeld G, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987;61:2017-23.
2. 2. Krowka JF, Stites DP, Jain S, et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989;83: 1198-203.
3. 3. Valentine FT, Paolino A, Saito A, Holzman RS. Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV Disease. AIDS Res Hum Retroviruses 1998;14(Suppl 2):S161-6.
4. 4. Moss RB, Richieri SP, Ferre F, et al. HIV-1-specific functional immune measurements as markers of disease progression. J Biomed Sci 1997;4:127-31.
5. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
6. 1 long-term survivor. AIDS Res Hum Retroviruses 1994;10:1703-11.
7. 7. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
8. 8. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998;177:898-904.
9. 9. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV) infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
10. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
11. 11. Balter M, Cohen J. AIDS research: international AIDS meeting injects a dose of realism. Science 1998;281:159-60.
12. + T cells. Science 1995;270:1811-5.
13. 13. Moss RB, Trauger RJ, Giermakowska WK, et al. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:343-50.
14. 14. Oliva A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998;102:223-31.
15. 15. Ferre F, Moss RB, Daigle AE, et al. Combination therapies against HIV-1 infection: exploring the concept of combining antiretroviral drug treatments with HIV-1 immune-based therapies in asymptomatic individuals. AIDS Patient Care STDs 1996;10:357-61.
16. 16. Prior CP, Gore R, Harter J, et al. Inactivation and purification of human immunodeficiency virus-1 as antigen for the treatment of HIV-1 infection. BioPharm 1996;9:22-34.
17. 17. Choi DJ, Dube S, Spicer TP, Slade HB, Jensen FC, Poiesz BJ. Sequence note: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses 1997;13:357-61.
18. 18. Getchell JP, Hicks DR, Srinivasan A, et al. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis 1987;156:833-7.
19. 19. LoGrippo GA. Investigations of the use of beta-propiolactone in virus inactivation. Ann NY Acad Sci 1960;83:578-94.
20. 20. Kitchen AD, Mann GF, Harrison JF, Zuckerman AJ. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox Sang 1989;56:223-9.
21. 21. Moss RB, Giermakowska W, Lanza P, et al. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 Immunogen, REMUNE™) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunol 1997;10:221-8.
22. 22. Moss RB, Wallace MR, Lanza P, et al. In vitro p24 antigen-stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin Diagn Lab Immunol 1998;5:308-12.
23. 23. Ullum H, Cozzi A, Victor J, et al. Production of β-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1β are associated with a decreased risk of HIV disease progression. J Infect Dis 1998;177:331-6.
24. 24. Benyoucef S, Hober D, De Groote D, et al. RANTES production in HIV-1 antigen-stimulated whole blood culture: relationship with type 1 immune response and plasma viral load in individuals infected with HIV-1. Scand J Immunol 1998;48:212-6.
25. 25. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-8.
26. 26. Shearer GM, Clerici M. Cytokine profiles in HIV type 1 disease and protection. AIDS Res Hum Retroviruses 1998;14(Suppl 2):S149-52.
27. 27. Moss RB, Li L, Giermakowska WK, et al. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (Remune) in HIV-1-seropositive subjects. J Hum Virol 1998;1:77-81.
28. 28. Kalams S, Buchbinder SP, Billingsley MJ, et al. Control of HIV replication requires virus-specific helper and CTL function and levels of CTL activity are in equilibrium with viral burden [abstract 31130]. In: Proceedings of the 12th World AIDS Conference (Geneva). Stockholm: International AIDS Society, 1998.
29. 29. Chang JCC, Diveley JP, Savary JR, Jensen FC. Adjuvant activity of incomplete Freund's adjuvant. Adv Drug Deliv Rev 1998;32:173-86.
30. 30. Pakker NG, Notermans DW, De Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998;4: 208-14.
31. + T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998;14:561-9.